Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
$18.70
-$0.04(-0.19%)
At close: 4:00 PM EST
$18.70
-$0.04(-0.19%)
Day’s Range― - ―
52-Week Range$14.02 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)54.50M
Market Cap
$35.83B
Enterprise Value$43.24B
Total Cash (Recent Filing)$1.14B
Total Debt (Recent Filing)$9.11B
Price to Earnings (P/E)25.1
Beta<0.01
Next Earnings
May 13, 2026EPS Estimate
0.26Next Dividend Ex-DateN/A
Dividend Yield4.85%
Share Statistics
EPS (TTM)0.27
Shares Outstanding1,916,011,600
10 Day Avg. Volume68,469,369
30 Day Avg. Volume54,495,236
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)4.20
Price to Sales (P/S)2.62
P/FCF Ratio30.38
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit4.96
Enterprise Value/Ebitda14.70
Forecast
1Y Price Target
$18.86Price Target Upside0.84% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceReported results showed sales and gross margin modestly above expectations, with lower operating expenses supporting earnings and indicating operational resilience.
Merger Clearance And Strategic GrowthShareholder approval cleared a major hurdle for the Kimberly‑Clark merger, increasing the likelihood of deal completion and opening opportunities to expand into higher‑growth consumer segments and revive underperforming brands.
Revenue Mix And PricingOrganic sales beat expectations driven by favorable price and product mix despite softer volumes, demonstrating pricing power and portfolio strength.
Bears Say
Category WeaknessWeaker seasonal patterns caused a contraction in the Self Care category, putting pressure on domestic sales momentum and highlighting vulnerability in core product lines.
Guidance Cancellation And Limited UpsideManagement's cancellation of forward guidance and the conference call amid the pending acquisition increased investor uncertainty, while the stock trading close to the deal's implied value limits potential upside for shareholders.
Legal Overhang And Judge ScrutinyCourt hearing comments indicated judges questioned exclusions and showed a tone favorable to plaintiffs, suggesting the acetaminophen litigation could be prolonged and increase legal uncertainty.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $14.02 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $35.83B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is May 13, 2026 which is in 84 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Feb 17, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 4.85%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.26.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,916,011,600 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.27 in its last earnings report, beating expectations of $0.22. Following the earnings report the stock price went up 2.248%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kenvue, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.86 (0.84% Upside)
$18.86 (0.84% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 870.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $111.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.06%
12-Months-Change
Fundamentals
Return on Equity
13.47%
Trailing 12-Months
Asset Growth
1.20%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.23% Self Care
27.43% Skin Health and Beauty
30.33% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
$18.86
▲(0.84% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
27.51% Mutual Funds
8.54% Other Institutional Investors
34.45% Public Companies and Individual Investors